EE+ POEM Archive
In patients with T2DM and CV disease, empagliflozin reduces CV and all-cause mortality (NNT = 38 over 3.3 years)
In patients with T2DM and CV disease, empagliflozin reduces CV and all-cause mortality (NNT = 38 over 3.3 years) is a topic covered in the EE+ POEM Archive.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "In Patients With T2DM and CV Disease, Empagliflozin Reduces CV and All-cause Mortality (NNT = 38 Over 3.3 Years)." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/428480/all/In_patients_with_T2DM_and_CV_disease__empagliflozin_reduces_CV_and_all_cause_mortality__NNT_=_38_over_3_3_years_.
In patients with T2DM and CV disease, empagliflozin reduces CV and all-cause mortality (NNT = 38 over 3.3 years). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428480/all/In_patients_with_T2DM_and_CV_disease__empagliflozin_reduces_CV_and_all_cause_mortality__NNT_=_38_over_3_3_years_. Accessed March 23, 2023.
In patients with T2DM and CV disease, empagliflozin reduces CV and all-cause mortality (NNT = 38 over 3.3 years). (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428480/all/In_patients_with_T2DM_and_CV_disease__empagliflozin_reduces_CV_and_all_cause_mortality__NNT_=_38_over_3_3_years_
In Patients With T2DM and CV Disease, Empagliflozin Reduces CV and All-cause Mortality (NNT = 38 Over 3.3 Years) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2023 March 23]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428480/all/In_patients_with_T2DM_and_CV_disease__empagliflozin_reduces_CV_and_all_cause_mortality__NNT_=_38_over_3_3_years_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - In patients with T2DM and CV disease, empagliflozin reduces CV and all-cause mortality (NNT = 38 over 3.3 years)
ID - 428480
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428480/all/In_patients_with_T2DM_and_CV_disease__empagliflozin_reduces_CV_and_all_cause_mortality__NNT_=_38_over_3_3_years_
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
